| Literature DB >> 26440943 |
Shiyi Cao1, Chen Yang1, Yong Gan1, Zuxun Lu1.
Abstract
PURPOSE: We aim to systematically summarize the available epidemiological evidence to identify the impact of environmental tobacco smoke on health.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26440943 PMCID: PMC4595077 DOI: 10.1371/journal.pone.0139907
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Identification of relevant meta-analyses.
Main characteristics of the included systematic reviews.
| Author | Year | Diseases | Number and design of included studies | Pooled odds ratio (95% confidence interval) |
|---|---|---|---|---|
| Lee CC | 2010 | pediatric invasive bacterial disease and bacterial carriage | 30 case-control studies for invasive bacterial disease | invasive bacterial disease: |
| 12 cross-sectional studies for bacterial carriage | 1.21 (95% CI 0.69–2.14) for invasive pneumococcal disease | |||
| 1.22 (95% CI 0.93–1.62) for invasive Hib disease. | ||||
| pharyngeal carriage: | ||||
| 1.68 (95% CI, 1.19–2.36) for Neisseria. meningitidies | ||||
| 1.66 (95% CI 1.33–2.07) for Streptococcus. pneumoniae | ||||
| 0.96 (95% CI 0.48–1.95) for Hib. | ||||
| Van Hemelrijck MJ, | 2009 | bladder cancer | 8 studies | 0.99 (95% CI 0.86–1.14) |
| 3 cohort | 1.19 (95% CI 0.88–1.62) for childhood passive smoking | |||
| 5 case-control | 0.90 (95% CI 0.79–1.02) for adulthood passive smoking | |||
| Jones DT | 2008 | inflammatory bowel disease | 13 case-control studies | 1.10 (95% CI 0.92–1.30) for Crohn's disease |
| 1.01 (95% CI 0.85–1.20) for ulcerative colitis | ||||
| Jones LL | 2011 | lower respiratory infections in infancy | 60 studies | 1.22 (95% CI 1.10–1.35) for paternal smoking |
| 32 cohort | 1.62 (95% CI 1.38–1.89) for both parents smoking | |||
| 15 case-control | 1.54 (95% CI 1.40–1.69) for any household member smoking. | |||
| 13 cross-sectional | ||||
| Zeng XT | 2012 | cervical cancer | 11 case-control studies | 1.73 (95% CI 1.35–2.21) |
| Strachan DP | 1998 | middle ear disease in children | 28 studies | 1.48 (95% CI 1.08–2.04) for recurrent otitis media, |
| 11 cohort | 1.38 (95% CI 1.23–1.55) for middle ear effusion | |||
| 13 case-control | 1.21 (95% CI 0.95–1.53) for glue ear. | |||
| 4 cross-sectional | ||||
| Murray RL | 2012 | invasive meningococcal disease in children | 18 studies | 2.18 (95% CI 1.63–2.92) |
| 2 cohort | 2.48 (95% CI 1.51–4.09) in children under 5 years. | |||
| 16 case-control | 2.26 (95% CI 1.54–3.31) for maternal smoking after birth | |||
| Zhou J | 2012 | pancreatic cancer | 10 studies | 1.12 (95% CI 0.89–1.43) during childhood. |
| 7 cohort | 1.23 (95% CI 0.86–1.77) during adulthood at home | |||
| 3 case-control | 0.94 (95% CI 0.67–1.33) during adulthood at work | |||
| Lin HH | 2007 | tuberculosis | 4 case-control studies | 4.01 (95% CI 2.54–6.34) |
| Saulyte J | 2014 | allergic rhinitis, allergic dermatitis, and food allergy in adults and children | 63 studies for allergic rhinitis | 1.10 (95% CI 1.06–1.15) |
| 9 cohort | 1.07 (95% CI 1.03–1.12) for allergic dermatitis | |||
| 3 case-control | 1.09 (95% CI 1.04–1.14) for allergic rhinitis | |||
| 51 cross-sectional | 1.43 (95% CI 1.12–1.83) for food allergy | |||
| 58 studies for allergic dermatitis | ||||
| 14 cohort | ||||
| 5 case-control | ||||
| 39 cross-sectional | ||||
| 6 studies for food allergies | ||||
| 5 cohort | ||||
| 1 cross-sectional | ||||
| Sun K | 2014 | diabetes | 6 cohort studies | 1.21 (95% CI 1.07–1.38) |
| Oono IP | 2011 | stroke | 20 studies | 1.25 (95% CI 1.12–1.38) |
| 10 cohort | 1.22 (95% CI 1.08–1.38) for cohort studies | |||
| 6 case-control | 1.41 (95% CI 1.15–1.72) for case-control studies | |||
| 4 cross-sectional | 1.03 (95% CI 0.69–1.53) for cross-sectional studies | |||
| Tinuoye O | 2013 | physician-diagnosed childhood asthma | 20 studies | 1.32 (95% CI 1.23–1.42) |
| 4 cohort | 1.26 (95% CI 0.91–1.73) for cohort studies | |||
| 2 case-control | 1.41 (95% CI 1.31–2.32) for case-control studies | |||
| 14 cross-sectional | 1.31 (95% CI 1.22–1.43) for cross-sectional studies | |||
| Yang Y | 2013 | breast cancer | 10 cohort studies. | 1.01 (95% CI 0.96–1.06) |
| 0.96 (95% CI 0.81–1.14) for passive smoking at home | ||||
| 1.01 (95% CI 0.93–1.10) for passive smoking in the workplace | ||||
| He J | 1999 | coronary heart disease | 18 studies | 1.25 (95% CI 1.17–1.32) |
| 10 cohort | 1.17 (95% CI 1.11–1.24) for passive smoking at home | |||
| 8 case-control | 1.11 (95% CI 1.00–1.23) for passive smoking in the workplace | |||
| Taylor R | 2007 | lung cancer | 55 studies | 1.27 (95% CI 1.17–1.37) |
| 7 cohort | 1.15 (95% CI 1.03–1.28) for North America | |||
| 25 population-based case-control | 1.31 (95% CI 1.16–1.48) for Asia | |||
| 23 non-population-based case-control | 1.31 (95% CI 1.24–1.52) for Europe |
Appraisal of the included meta-analyses on the impact of passive smoking on various diseases.
| Author | ‘A priori’ design provided | Duplicate study selection/data extraction | Comprehensive literature search | Status of publication as inclusion criteria | List of studies included/excluded provided | Characteristics of included studies documented | Scientific quality assessed and documented | Appropriate formulation of conclusions | Appropriate methods of combining studies; | Assessment of publication bias; and | Conflict of interest statement. | Total yes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lee CC | yes | yes | yes | no | yes | yes | no | yes | yes | yes | yes | 9 |
| Van H MJ, | no | no | no | yes | yes | yes | no | no | yes | yes | yes | 6 |
| Jones DT | yes | yes | yes | no | yes | yes | yes | no | yes | yes | yes | 9 |
| Jones LL | yes | yes | yes | no | yes | no | yes | yes | yes | yes | yes | 9 |
| Zeng XT | no | yes | no | yes | yes | yes | yes | no | yes | yes | no | 7 |
| Strachan DP | no | no | yes | no | no | yes | no | no | yes | no | no | 3 |
| Murray RL | yes | yes | yes | no | yes | yes | no | no | yes | yes | yes | 8 |
| Zhou J | no | no | yes | no | no | yes | no | no | yes | yes | yes | 5 |
| Lin HH | no | yes | no | no | yes | yes | yes | yes | yes | yes | yes | 8 |
| Saulyte J | no | yes | yes | no | yes | yes | yes | no | yes | yes | yes | 8 |
| Sun K | no | no | yes | no | yes | yes | yes | no | yes | no | yes | 6 |
| Oono IP | no | yes | no | no | yes | yes | no | yes | yes | yes | no | 6 |
| Tinuoye O | no | no | yes | no | no | yes | no | no | yes | yes | yes | 5 |
| Yang Y | yes | yes | yes | no | yes | yes | yes | yes | yes | yes | yes | 10 |
| He J | no | yes | yes | no | no | yes | no | no | no | yes | no | 4 |
| Taylor R | yes | yes | yes | yes | yes | yes | no | yes | yes | yes | yes | 10 |
Fig 2Summary of estimates of associations between passive smoking and the risk of specific diseases or health problems.